These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 16454695)

  • 1. Topotecan is a substrate for multidrug resistance associated protein 4.
    Tian Q; Zhang J; Chan SY; Tan TM; Duan W; Huang M; Zhu YZ; Chan E; Yu Q; Nie YQ; Ho PC; Li Q; Ng KY; Yang HY; Wei H; Bian JS; Zhou SF
    Curr Drug Metab; 2006 Jan; 7(1):105-18. PubMed ID: 16454695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human multidrug resistance associated protein 4 confers resistance to camptothecins.
    Tian Q; Zhang J; Tan TM; Chan E; Duan W; Chan SY; Boelsterli UA; Ho PC; Yang H; Bian JS; Huang M; Zhu YZ; Xiong W; Li X; Zhou S
    Pharm Res; 2005 Nov; 22(11):1837-53. PubMed ID: 16132345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
    Ma J; Maliepaard M; Nooter K; Loos WJ; Kolker HJ; Verweij J; Stoter G; Schellens JH
    Br J Cancer; 1998 May; 77(10):1645-52. PubMed ID: 9635842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
    Erlichman C; Boerner SA; Hallgren CG; Spieker R; Wang XY; James CD; Scheffer GL; Maliepaard M; Ross DD; Bible KC; Kaufmann SH
    Cancer Res; 2001 Jan; 61(2):739-48. PubMed ID: 11212277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells.
    Lee K; Klein-Szanto AJ; Kruh GD
    J Natl Cancer Inst; 2000 Dec; 92(23):1934-40. PubMed ID: 11106685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography.
    Yamasaki T; Fujinaga M; Kawamura K; Hatori A; Yui J; Nengaki N; Ogawa M; Yoshida Y; Wakizaka H; Yanamoto K; Fukumura T; Zhang MR
    Nucl Med Biol; 2011 Jul; 38(5):707-14. PubMed ID: 21718946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells.
    Jia P; Wu S; Li F; Xu Q; Wu M; Chen G; Liao G; Wang S; Zhou J; Lu Y; Ma D
    Int J Gynecol Cancer; 2005; 15(6):1042-8. PubMed ID: 16343180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
    Hendricks CB; Rowinsky EK; Grochow LB; Donehower RC; Kaufmann SH
    Cancer Res; 1992 Apr; 52(8):2268-78. PubMed ID: 1348448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of SN38-resistant T47D breast cancer cell sublines overexpressing BCRP, MRP1, MRP2, MRP3, and MRP4.
    Lee HJ; Choi CH
    BMC Cancer; 2022 Apr; 22(1):446. PubMed ID: 35461219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antisense oligonucleotide reverses topotecan-resistant ovarian cancer cells].
    Jia P; Wu SB; Xu Q; Wu MF; Gao QL; Liao GN; Lu YP; Ma D
    Ai Zheng; 2003 Dec; 22(12):1296-300. PubMed ID: 14693055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4).
    Zhang J; Ng KY; Ho PC
    AAPS J; 2010 Sep; 12(3):300-8. PubMed ID: 20405259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy.
    Leggas M; Adachi M; Scheffer GL; Sun D; Wielinga P; Du G; Mercer KE; Zhuang Y; Panetta JC; Johnston B; Scheper RJ; Stewart CF; Schuetz JD
    Mol Cell Biol; 2004 Sep; 24(17):7612-21. PubMed ID: 15314169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
    Rajendra R; Gounder MK; Saleem A; Schellens JH; Ross DD; Bates SE; Sinko P; Rubin EH
    Cancer Res; 2003 Jun; 63(12):3228-33. PubMed ID: 12810652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.
    Parmakhtiar B; Burger RA; Kim JH; Fruehauf JP
    Mol Cancer Res; 2019 Aug; 17(8):1675-1686. PubMed ID: 31088908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The mechanism of topotecan resistance in ovarian cancer cell line].
    Jia P; Wu SB; Li F; Xu Q; Wu MF; Liao GN; Lu YP; Ma D
    Zhonghua Zhong Liu Za Zhi; 2004 Mar; 26(3):139-42. PubMed ID: 15196431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.
    Gounder MK; Nazar AS; Saleem A; Pungaliya P; Kulkarni D; Versace R; Rubin EH
    Invest New Drugs; 2008 Jun; 26(3):205-13. PubMed ID: 17943230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
    Yang CH; Huang CJ; Yang CS; Chu YC; Cheng AL; Whang-Peng J; Yang PC
    Cancer Res; 2005 Aug; 65(15):6943-9. PubMed ID: 16061679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin as a fluorescent reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high content screening of anticancer agents.
    Sampson A; Peterson BG; Tan KW; Iram SH
    Biomed Pharmacother; 2019 Oct; 118():109289. PubMed ID: 31401398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.